We advised European Biotech Acquisition, a SPAC, on its IPO and Nasdaq listing

Davis Polk advised European Biotech Acquisition Corp. on its $120 million initial public offering of 12,000,000 units. Each unit had an initial offering price of $10 and consists of one Class A ordinary share and one-third of one redeemable warrant. The units, the shares and the warrants are listed on the Nasdaq Capital Market. 

European Biotech Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated for the purpose of effecting a business combination with one or more businesses. The company intends to capitalize on the ability of its management team to identify promising opportunities in the life sciences industry in Europe.

The Davis Polk corporate team included partners Derek Dostal and Yasin Keshvargar and associates Arisa Akashi and Dylan H. Lojac. The tax team included partner Lucy W. Farr and associate Daniel L. Jose. All members of the Davis Polk team are based in the New York office.